Heart transplant recipient survivor from COVID-19: The first case of Turkey
| Autor: | Ahmet Rüçhan Akar, Mehmet Cakici, Bahadir Inan, Alpay Azap, Güle Çınar, Cahit Saricaoglu, Tamer Sayin, Irem Dincer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pediatrics medicine.medical_specialty Isolation (health care) medicine.medical_treatment Vital signs Case Report Disease simmunocompromised 030204 cardiovascular system & hematology 030230 surgery Favipiravir heart transplantation Loading dose 03 medical and health sciences 0302 clinical medicine medicine medicine.diagnostic_test business.industry COVID-19 Immunosuppression Hydroxychloroquine Surgery Cardiology and Cardiovascular Medicine business Electrocardiography medicine.drug |
| Zdroj: | Turkish Journal of Thoracic and Cardiovascular Surgery |
| ISSN: | 2149-8156 1301-5680 |
| Popis: | Any highly infectious and rapidly spreading disease is a primary concern for immunocompromised solid organ transplant recipients. The number of data about the spectrum of clinical illness, the treatment modalities, and the outcomes of COVID-19 in this vulnerable population is scant and still remains empirical. Herein, we report the first COVID-19 case of a heart transplant recipient in Turkey who presented with fever, postnasal discharge, and myalgias for two days. The possibility of lung involvement was ruled out by thoracic computed tomography. Despite stable vital signs, we reduced the intensity of immunosuppressive therapy and maintained home self-isolation promptly. We also commenced a five-day course of hydroxychloroquine 200 mg q12h initially. After confirmation of real-time reverse-transcriptase-polymerase-chain-reaction testing of the nasopharyngeal swab positive for COVID-19, the patient was hospitalized. After a loading dose of favipiravir 1,600 mg b.i.d., the patient received a five-day course of favipiravir 600 mg q12h. He was discharged with cure after 23 days of hospital isolation and treatment. In conclusion, treatment process can be affected by the daily electrocardiography, hand-held portable echocardiography, myocardial injury markers, and pulse oximeter for self-monitoring in the follow-up of previous heart transplant recipients suffering from COVID-19. The lack of treatment protocols in the solid organ transplant recipients with COVID-19 infection and the controversies about the protective effect of immunosuppression invite a global and update discussion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|